Alligator Bioscience AB Overview
Pro stress-test →Alligator Bioscience is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. The company's lead drug candidate mitazalimab is currently ready for Phase 3 development, and has previously presented unprecedented survival data at 30-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1.
Strategic Profile
Pro stress-test →Alligator is a clinical-stage biotechnology company focused on the CD40 receptor with a validated approach that promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment. The company develops products using technology platforms including ALLIGATOR-GOLD, ALLIGATOR-FAB, FIND, and RUBY, with collaboration agreements with Aptevo Therapeutics, Orion Corporation, BioArctic AB, and Abclon Inc.
Competitive Landscape
Pro stress-test →Alligator specializes in tumor-targeted immunotherapies, particularly agonist mono- and bispecific antibodies, active in early stages of drug development from concept to Phase II clinical trials. Primary competitors in CD40 and immuno-oncology space include larger established biotechs and pharma companies with more diversified portfolios and stronger balance sheets.
Industry Context
Alligator Bioscience AB operates in Biotechnology - Oncology/Immuno-oncology.
Key facts
Founded: 2000 · Headquarters: Lund, Sweden · Employees: ~45 · Revenue: SEK 57.7M (2024) · Market cap: SEK 45-102M (~$4.5-10M USD)